SynthesisBreast cancer research and treatment2018

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.

Y F Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.